Alendronate sodium hydrate (Synonyms: Adronat, Fosamax, G-704650, MK-217) |
| Catalog No.GC10348 |
Alendronate sodium hydrate is a nitrogen-containing bisphosphonate that strongly inhibits bone resorption, it is often used in research on the prevention and treatment of osteoporosis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 121268-17-5
Sample solution is provided at 25 µL, 10mM.
Alendronate sodium hydrate is a nitrogen-containing bisphosphonate that strongly inhibits bone resorption, it is often used in research on the prevention and treatment of osteoporosis [1]. Alendronate sodium hydrate has a strong affinity for circulating calcium and minerals on the bone surface, and inhibits the enzyme activity in osteoclasts, thereby hindering the dissolution of bone tissue and the degradation of collagen [2].
Alendronate sodium hydrate (10-4mol/L) incubated for 48 hours significantly reduced the collagen synthesis of osteoblasts. Alendronate sodium hydrate at a concentration of 10-12-10-5mol/L has no effect on calcium deposition in normal human osteoblasts [3].
Alendronate sodium hydrate (25mg/kg) treatment twice each week for 8 weeks, exhibited a reversal of mouse liver fibrosis to a significant extent, and the expression of α-SMA positive cells in the hepatic fibrosis area was significantly reduced in CCl4 induced liver fibrosis mouse model [4]. Alendronate sodium hydrate (0.01 to 0.25mg/kg, s.c., 11 days) preserves alveolar bone resorption and has anti-inflammatory and antibacterial activities in experimental periodontitis [5]. Alendronate sodium hydrate pretreated mice (0.1mg/kg twice a week or once a week) combined with paclitaxel administration (10-50mg/kg/day twice a week or once a week) statistically significantly blocked the growth of PC3 ML tumors in bone marrow and soft tissue. And significantly improve survival time [6].
References:
[1] Bell NH, Johnson RH. Bisphosphonates in the treatment of osteoporosis. Endocrine. 1997 Apr;6:203-6.
[2] Iwamoto J, Miyata A, Sato Y, Takeda T, Matsumoto H. Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures. Therapeutics and Clinical Risk Management. 2009 Oct 12:773-9.
[3] Garcia-Moreno C, Serrano S, Nacher M, Farré M, Diez A, Marinoso ML, Carbonell J, Mellibovsky L, Nogués X, Ballester J, Aubía J. Effect of alendronate on cultured normal human osteoblasts. Bone. 1998 Mar 1;22(3):233-9.
[4] Bi WR, Jin CX, Xu GT, Yang CQ. Effect of alendronate sodium on the expression of mesenchymal-epithelial transition markers in mice with liver fibrosis. Experimental and Therapeutic Medicine. 2013 Jan;5(1):247-52.
[5] Menezes AM, Rocha FA, Chaves HV, Carvalho CB, Ribeiro RA, Brito GA. Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. Journal of periodontology. 2005 Nov;76(11):1901-9.
[6] Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion & Metastasis. 1996 Jan 1;16(3):116-31.
| Cell experiment [1]: | |
Cell lines | Human bone cells |
Preparation Method | A stock solution of Alendronate sodium hydrate was prepared by dissolving at a concentration of 10mol/L in DMEM. Culture media were prepared at final concentrations of alendronate between 10-12 to 10-1mol/L, with 1:10 serial dilutions of the stock solutions. Medium with or without Alendronate sodium hydrate was then added and the cells incubated for 48 or 96h. |
Reaction Conditions | 10-12 to 10-1mol/L; 48 or 96h |
Applications | After 96 h of incubation, cell viability was significantly decreased at the Alendronate sodium hydrate concentration of 10-4mol/L. |
| Animal experiment [2]: | |
Animal models | Ovariectomized female Wistar rats |
Preparation Method | The animals were divided into four groups: ovariectomized (OVX group); ovariectomized and treated with 1mg/kg or 2mg/kg Alendronate sodium hydrate (ALN) salt diluted in saline solution (Group OVX + ALN1 and Group OVX + ALN2); and a sham operated group used as the control. |
Dosage form | 1 or 2mg/kg; s.c.; twice a week |
Applications | The rats began treatment immediately following ovariectomy and both doses of Alendronate sodium hydrate proved effectiveness in controlling mineral loss. |
References: | |
| Cas No. | 121268-17-5 | SDF | |
| Synonyms | Adronat, Fosamax, G-704650, MK-217 | ||
| Chemical Name | sodium hydrogen(4-amino-1-hydroxy-1-phosphonobutyl)phosphonate trihydrate | ||
| Canonical SMILES | [O-]P(O[H])(C(O[H])(C([H])([H])C([H])([H])C([H])([H])N([H])[H])P(O[H])(O[H])=O)=O.[H]O[H].[H]O[H].[H]O[H].[Na+] | ||
| Formula | C4H18NNaO10P2 | M.Wt | 325.12 |
| Solubility | ≥ 5.57mg/mL in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0758 mL | 15.3789 mL | 30.7579 mL |
| 5 mM | 0.6152 mL | 3.0758 mL | 6.1516 mL |
| 10 mM | 0.3076 mL | 1.5379 mL | 3.0758 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *